featured
Crovalimab vs Eculizumab for Complement Inhibition–Naïve Paroxysmal Nocturnal Hemoglobinuria
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
Am. J. Hematol 2024 Jun 17;[EPub Ahead of Print], A Röth, G He, H Tong, Z Lin, X Wang, C Chai-Adisaksopha, JH Lee, A Brodsky, C Hantaweepant, TE Dumagay, R Demichelis-Gómez, P Rojnuckarin, J Sun, M Höglund, JH Jang, A Gaya, F Silva, N Obara, RJ Kelly, L Beveridge, S Buatois, S Chebon, B Gentile, P Lundberg, S Sreckovic, JI Nishimura, A Risitano, B HanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.